Smartlab Europe

Press Releases

Medivir Streamlines Operations by Divesting Cross Pharma, its Parallel Import Business

Medivir AB (STO:MVIR-B) today announced that the company has signed an agreement to sell its wholly owned subsidiary Cross Pharma AB to Unimedic AB a subsidiary of the Swedish listed company MedCap AB. The intention is to close the...

Quintiles Named Britain’s Healthiest Large Company

Quintiles has been named “Britain’s Healthiest Large Company” in the first survey of its kind to identify organizations in Britain with outstanding employee health and wellness programs. Quintiles also received top honors as overall healthiest...

Obesity is a Disease: The American Medical Association Agrees with the American Association of Clinical Endocrinologists

The American Association of Clinical Endocrinologists (AACE) applauds the American Medical Association (AMA) House of Delegates for its action today to approve a resolution recognizing obesity as a disease state requiring a range of interventions to advance obesity treatment...

Preclinical program of translational research tasked with identifying new target proteins

Sanofi and the Curie Institute, through its Curie-Cancer partnership under the Institut Carnot label, today announce the establishment of a three-year research collaboration to identify new therapeutic targets for the development of treatments for ovarian cancer. ...

Inspirational Sessions and Important Connections at Groundbreaking Scientific Healthcare Conference

The inaugural World Research and Innovation Congress took place at the Steigenberger Grandhotel in Brussels on 5 and 6 June. It was a truly international event attended by senior scientific healthcare delegates from over 50 different countries with the...

Clovis Oncology Announces Upsizing and Pricing of Public Offering of Common Stock

Clovis Oncology announced today the pricing of an underwritten public offering of 3333334 shares of its common stock at $72.00 per share before underwriting discounts and commissions. The size of the offering was upsized from...

Targovax AS Raises $3.6 Million in Private and Public Support for TG01 Pancreatic Cancer Vaccine Development

Cancer vaccine specialist Targovax today announced that it has raised a total of $3.6 million to accelerate development of its RAS mutation-targeted therapeutic cancer vaccine pipeline specifically lead candidate TG01 for pancreatic cancer. The funds...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »